Hypertension and hepatic steatosis

Current Hypertension Reports

Volumn 10, Issue 3, 2008, Pages 182-187

  Brookes, Matthew J ^b   Iqbal, Tariq H ^b   Cooper, Brian T ^a  

^a CITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASCORBIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DILTIAZEM; ESTROGEN; LOSARTAN; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; ROSIGLITAZONE; TAMOXIFEN; TETRACYCLINE DERIVATIVE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID; VALPROIC ACID;

AGE DISTRIBUTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; FATTY LIVER; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; NONHUMAN; REVIEW;

DISEASE PROGRESSION; FATTY LIVER; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; RISK FACTORS;

EID: 56349106977     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0035-9     Document Type: Review

References (50)

1. Brookes MJ, Cooper BT: Hypertension and fatty liver: guilty by association? J Hum Hypertens 2007, 21:264-270.
2. Harrison SA, Day CP: Benefits of lifestyle modification in NAFLD. Gut 2007, 56:1760-1769.
3. Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600-606.
4. Duvnjak M, Lerotic I, Barsic N, et al.: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007, 13:4539-4550.
5. Lee DH, Ha MH, Kim KY, et al.: Gamma-glutamyltransferase: an effect modifier in the association between age and hypertension in a 4-year follow-up study. J Hum Hypertens 2004, 18:803-807.
6. Stranges S, Trevisan M, Dorn JM, et al.: Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension 2005, 46:1186-1193.
7. Donati G, Stagni B, Piscaglia F, et al.: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004, 53:1020-1023.
8. Dam-Larsen S, Franzmann M, Andersen IB, et al.: Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
9. McCullough AJ: The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:521-533, viii.
10. Liou I, Kowdley KV: Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006, 40(3 Suppl 1): S11-S16.
11. Donnelly KL, Smith CI, Schwarzenberg SJ, et al.: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
12. Cai DS, Yuan MS, Frantz DF, et al.: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005, 11:183-190.
13. Samuel VT, Liu ZX, Qu XQ, et al.: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345-32353.
14. Albano E, Mottaran E, Occhino G, et al.: Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005, 22:71-73.
15. Albano E, Mottaran E, Vidali M, et al.: Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005, 54:987-993.
16. Zamara E, Novo E, Marra F, et al.: 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004, 40:60-68.
17. Cortez-Pinto H, de Moura MC, Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006, 44:197-208.
18. Ribeiro PS, Cortez-Pinto H, Sola S, et al.: Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappa B in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004, 99:1708-1717.
19. Arkan MC, Hevener AL, Greten FR, et al.: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191-198.
20. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
21. Angulo P, Alba LM, Petrovic LM, et al.: Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004, 41:943-949.
22. Yokohama S, Tokusashi Y, Nakamura K, et al.: Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006, 12:322-326.
23. Targher G, Bertolini L, Rodella S, et al.: Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006, 64:337-341.
24. Ataseven H, Yildirim MH, Yalniz M, et al.: The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2005, 68:221-225.
25. Szczepaniak LS, Nurenberg P, Leonard D, et al.: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
26. Yeh MM, Brunt EM: Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007, 128:837-847.
27. O'Leary VB, Marchetti CM, Krishnan RK, et al.: Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol 2006, 100:1584-1589.
28. Tiikkainen M, Bergholm R, Rissanen A, et al.: Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004, 79:22-30.
29. Zelber-Sagi S, Kessler A, Brazowsky E, et al.: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4:639-644.
30. Stratopoulos C, Papakonstantinou A, Terzis I, et al.: Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005, 15:1154-1160.
31. Jaskiewicz K, Raczynska S, Rzepko R, et al.: Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 2006, 51:21-26.
32. Shaffer EA: Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol 2006, 40:S44-S50.
33. Barker KB, Palekar NA, Bowers SP, et al.: Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101:368-373.
34. Uygun A, Kadayifci A, Isik AT, et al.: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
35. Bugianesi E, Gentilcore E, Manini R, et al.: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005, 100:1082-1090.
36. Duseja A, Das A, Dhiman RK, et al.: Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007, 6:222-226.
37. Kawaguchi K, Sakaida I, Tsuchiya M, et al.: Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004, 315:187-195.
38. Promrat K, Lutchman G, Uwaifo GI, et al.: A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
39. Sanyal AJ, Mofrad PS, Contos MJ, et al.: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2:1107-1115.
40. Lutchman G, Promrat K, Kleiner DE, et al.: Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006, 4:1048-1052.
41. Ono M, Ikegami H, Fujisawa T, et al.: Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metabolism 2005, 54:529-532.
42. Wang CH, Leung CH, Liu SC, et al.: Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease. J Formos Med Assoc 2006, 105:743-752.
43. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
44. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, et al.: A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
45. Hatzitolios A, Savopoulos C, Lazaraki G, et al.: Efficacy of omega-3 fatty acids, atorvastatin and orlistat in nonalcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004, 23:131-134.
46. Lindor KD, Kowdley KV, Heathcote EJ, et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39:770-778.
47. Dufour JF, Oneta CM, Gonvers JJ, et al.: Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4:1537-1543.
48. Kanno K, Tazuma S, Nishioka T, et al.: Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci 2005, 50:942-948.
49. Yokohama S, Yoneda M, Haneda M, et al.: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
50. Satapathy SK, Sakhuja P, Malhotra V, et al.: Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:634-638.